ADVANCES IN THE DRUG-TREATMENT OF ALZHEIMERS-DISEASE

Authors
Citation
Be. Leonard, ADVANCES IN THE DRUG-TREATMENT OF ALZHEIMERS-DISEASE, Human psychopharmacology, 13(2), 1998, pp. 83-90
Citations number
48
Categorie Soggetti
Psychiatry,"Pharmacology & Pharmacy","Clinical Neurology
Journal title
ISSN journal
08856222
Volume
13
Issue
2
Year of publication
1998
Pages
83 - 90
Database
ISI
SICI code
0885-6222(1998)13:2<83:AITDOA>2.0.ZU;2-Q
Abstract
There are two main approaches to the treatment of Alzheimer's disease. The first approach is to prevent the neurodegenerative changes that u ltimately cause irreversible damage to the brain. As the excessive for mation of beta-amyloid protein appears to play a primary role in the n eurodegenerative process, attempts have been made to block the synthes is of this protein. Secondary changes that may be initiated by beta-am yloid include local inflammatory factors, in particular cytokines 1 an d 6. There is evidence that nonsteroidal anti-inflammatory drugs such as indomethacin may have a role to play in preventing such inflammator y changes. The second approach is to slow the decline of the neuronal degeneration and to treat the symptoms of the disease. As many of the core symptoms appear to be associated with a degeneration of the corti cal cholinergic system, centrally acting anticholinesterases such as t acrine and donepazil have been shown to be helpful in a minority of pa tients. An alternative approach to treating the cause of brain damage in Alzheimer's disease is to administer neurotrophic factors which cou ld stimulate neuronal growth and development. So far, these approaches are only experimental. Other approaches involve drugs used to reduce free radical formation. (C) 1998 John Wiley & Sons, Ltd.